Former Eli Lilly execs donate $20 million to establish IU Health clinical institute
Two former Eli Lilly executives and their families will donate $20 million to IU Health Foundation — the largest philanthropic gift in the foundation's history — to establish the Institute for Clinical Innovation, a hub for groundbreaking disease detection and treatment.
IU Health will match the gift, bringing the total investment to $40 million shared between the health system and the medical school. The IU Health Foundation acts as the philanthropic arm of IU Health's statewide health care system.
Housed in the massive IU hospital complex under construction on the north side of downtown, the institute will accelerate the speed of medical research in Indiana and provide clinicians and researchers with more resources. IU Health leaders say they hope the investment will triple the number of patients in clinical trials. They hope to enroll 75,000 patients in clinical trials each year and within five years enroll 300,000 people in the Indiana Biobank initiative.
Indianapolis residents Sarah and John Lechleiter and Deborah and Randall Tobias partnered on the donation that will benefit patients across Indiana. Randall Tobias held the title of chair, president and CEO of Eli Lilly from 1993-2003, before he was nominated by President George W. Bush to lead the U.S. effort to fight against the global HIV/AIDS epidemic. John Lechleiter served as CEO of the pharmaceutical giant from 2008-2017 before handing over the reins to current CEO Dave Ricks.
'Our families share a commitment to advancing the future of healthcare for our Hoosier neighbors,' the Tobiases and Lechleiters said in a joint statement. 'This gift will support IU Health and IU School of Medicine in their joint efforts to expand clinical trial participation in our state for the benefit of patients in Indiana and around the globe.'
'The Lechleiter and Tobias families could have made this gift anywhere in the world. Choosing IU Health and IU School of Medicine demonstrates immense trust in our researchers and caregivers,' IU Health President and CEO Dennis Murphy said. 'Thanks to this commitment, our patients will get early access to life-saving treatments and The Institute for Clinical Innovation will become a destination for leading-edge healthcare.'
IU Health's $2.31 billion hospital complex, which will replace the aging IU Health Methodist Hospital, is expected to open in late 2027.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Oakland County issues alert for measles exposure site in Rochester Hills
FOX 2 - The Oakland County Health Division is notifying the public about a Rochester Hills measles exposure site involving a person from another county. The exposure site is a medical office building at 3950 S. Rochester Road at the corner of South Boulevard on Tuesday, June 3, according to a release from the Oakland County Health Division. Anyone there between 8 a.m. and 7:30 p.m. may have been exposed to measles. If you think you were exposed to measles at this location on June 3, Immune Globulin (IG) treatment is effective within six days of exposure for high-risk individuals. Those considered high-risk include women who are pregnant, unvaccinated children under age 5 and those who have a weakened immune system due to illness and disease including diabetes or HIV, malnutrition and/or medications. If you are not eligible for IG, monitor symptoms through June 24. If symptoms develop, call ahead to your health care provider. Individuals born in or before 1957 are considered immune. Measles is a highly contagious, vaccine-preventable disease that is spread by direct person-to-person contact and through the air. The Health Division recommends unvaccinated individuals ages 1 year and older receive a measles vaccination to protect themselves and those around them. Anyone who doesn't have a record of two MMR vaccines, unsure if they've have been vaccinated, or unsure if you've had measles in the past, needs to contact their health care provider. Measles can live for up to two hours in the air where an infected person coughed or sneezed. Symptoms of measles usually begin 7-14 days after exposure, but can appear up to 21 days after exposure, and may include: High fever (may spike to over 104°F Cough Runny nose Red, watery eyes (conjunctivitis) Tiny white spots on the inner cheeks, gums and roof of mouth (Koplik Spots) 2-3 days after symptoms begin. A rash that is red, raised, blotchy; usually starts on face, spreads to trunk, arms and legs 3-5 days after symptoms begin. The MMR vaccine is available through some health care providers, Oakland County Health Division offices in Southfield and Pontiac, and many pharmacies. Health Division offices are located at the following addresses: North Oakland Health Center, 1200 N. Telegraph Road, Building 34 East, Pontiac South Oakland Health Center, 27725 Greenfield Road, Southfield. Health Division clinics hours are Monday, Wednesday and Friday 8:30 a.m. – 5 p.m. Tuesday 9:30 a.m. – 6 p.m. and Thursday 7:30 a.m. – 5 p.m. Visit for more information on measles, or contact Nurse on Call, 8:30 a.m. to 5 p.m. Monday through Friday, at 800-848-5533 or noc@
Yahoo
8 hours ago
- Yahoo
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.
UPI
10 hours ago
- UPI
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.
